Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant
Product Name |
Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant |
CAS |
366789-02-8 |
Appearance |
White powder |
Molecular formula |
C19H18ClN3O5S |
Molecular Weight |
435.8813 |
Assay |
98% |
Shelf Life |
24 months when properly stored |
Storage |
Keep in a cool, dry, dark location |
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png) |
What is Rivaroxaban?
Rivaroxaban is an oral anticoagulant. It is an orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible
|
Function and Application of Rivaroxaban
Rivaroxaban can be used to prevent strokes in those with atrial fibrillation due to causes other than heart valvedisease,
and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke)
Rivaroxaban can also be used to prevent the formation of blood clots in the veins (deep venous thrombosis) in adults who
have had an operation to replace a hip or knee and for treatment and prevention of acute deep venous thrombosis in adults.
It can not be used for prevention of venous thrombosis in hospitalized medically ill patients.
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png)
Rivaroxaban is not indicated for prosthetic heart valves or for mitral stenosis.
Rivaroxaban is not indicated as an add-on treatment for dual antiplatelet therapy in the secondary prevention of coronary
incidents (double and triple therapy). In Europe, however, a 2.5-mg twice-daily dose was approved by the EuropeanCommission
after a recommendation by the European Medicines Agency (EMA) for the prevention of atherothrombotic events in adult patients
after an acute coronary syndrome (ACS) with elevated cardiac biomarkers co-administered with acetylsalicylic acid (ASA) alone o
r with ASA plus clopidogrel or ticlopidine.
Company Information
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png)
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png)
Our Certificate
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png)
Our Service
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png)
Our Research
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png)
Packaging & Logistics
Package:
1kg per Foil Bag, 10 Bags per carton. 25 kg per Drum. Or Customized Package.
2. Shipping Advise:
1. By Express
------Suitable for under 50kg, Fast:3-4 days. High cost; Door to door service. Easy to pick up the goods.
2. By Air
------Suitable for more than 50 kg, Fast:4-5 days, High cost, airport to airport. professional broker needed.
3. By sea
------Suitable for more than 500kg. Slow: 15-45 days, Low cost. Port to Port, professional broker needed.
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png)
why choose us ?
![Pharmaceutical Intermediate Rivaroxaban CAS 366789-02-8 Used in New Anticoagulant](//www.micstatic.com/athena/img/transparent.png)